摘要
目的分析探究血清标志物及白细胞介素-10(IL-10)对聚乙二醇干扰素α治疗慢性乙型肝炎(CHB)临床效果的预测价值。方法回顾性分析2023年1月至2024年1月于来宾市人民医院就诊的80例CHB患者的临床资料,患者均采用聚乙二醇干扰素α治疗,根据治疗后临床效果将其分为应答组(n=33)和非应答组(n=47)。采用单因素分析影响聚乙二醇干扰素α治疗CHB效果的因素,采用logistic回归分析影响聚乙二醇干扰素α治疗CHB临床效果的多因素,绘制受试者工作特征(ROC)曲线分析血清标志物与细胞因子水平预测聚乙二醇干扰素α对CHB治疗效果的预测价值。结果应答组中,乙型肝炎病毒脱氧核糖核酸(HBV-DNA)、乙型肝炎表面抗原(HbsAg)、IL-10的水平均低于非应答组,差异有统计学意义(P<0.05)。采用logistic回归方法分析影响聚乙二醇干扰素α治疗CHB临床效果的因素,HBV-DNA、HbsAg、IL-10均为聚乙二醇干扰素α在CHB治疗中临床效果的独立影响因素(P<0.05)。ROC曲线显示,HBV-DNA、HbsAg、IL-10联合预测聚乙二醇干扰素α治疗CHB临床效果的AUC为0.935。结论HBV-DNA、HbsAg、IL-10均为影响聚乙二醇干扰素α在CHB治疗中临床效果的相关因素,其水平对聚乙二醇干扰素α治疗CHB的效果具有较高的预测价值,通过早期监测,可以有效地预判患者的治疗反应,进而能为优化治疗方案提供有力支持。
Objective To analyze and explore the predictive value of serum biomarkers and interleukin-10(IL-10)on the clinical efficacy of pegylated interferon alpha in the treatment of chronic hepatitis B(CHB).Methods A retrospective analysis was conducted on the clinical data of 80 patients with CHB who were treated at Laibin People's Hospital from January 2023 to January 2024.All poctients received pegylated interferon therapy,and were subsequently classified into responder group(n=33)and non-responder group(n=47)based on their clinical response to treatment.Univariate analysis was employed to investigate factors influencing the efficacy of pegylated interferon in treating CHB.Moreover,a multivariate analysis utilizing logistic regression was performed to ascertain the primary factors influencing the clinical results of pegylated interferon treatment in patients with CHB.Additionally,receiver operating characteristic(ROC)curve analysis was conducted to evaluate the prognostic utility of serum biomarkers and cytokine levels in predicting the therapeutic response to pegylated interferon in these patients.Results In the responder group,the levels of hepatitis B virus deoxyribonucleic acid(HBV-DNA),hepatitis B surface antigen(HbsAg),and IL-10 were lower than those in the non-responder group,and the differences were statistically significant(P<0.05).The logistic regression method was used to analyze the factors affecting the clinical efficacy of pegylated interferon alpha in the treatment of CHB.HBV-DNA,HbsAg,and IL-10 were all independent influencing factors of the clinical efficacy of pegylated interferon alpha in CHB treatment(P<0.05).The ROC curve showed that the AUC of the combination of HBV-DNA,HbsAg,and IL-10 in predicting the clinical efficacy of pegylated interferon alpha in the treatment of CHB was 0.935.Conclusion HBV-DNA,HbsAg,and IL-10 are all related factors that affect the clinical efficacy of pegylated interferon alpha in the treatment of CHB.Their levels have high predictive value for the effectiveness of pegylated interferon alpha in the treatment of CHB.Early monitoring can effectively predict the patient's treatment response and provide strong support for optimizing treatment plans.
作者
梁洁琼
兰利梅
叶玉萍
周巧玉
宁梅芳
LIANG Jieqiong;LAN Limei;YE Yuping;ZHOU Qiaoyu;NING Meifang(Department of Laboratory Medicine,Laibin People's Hospital,Guangxi Zhuang Autonomous Region,Laibin546199,China;Department of Laboratory Medicine,the First Affiliated Hospital of Guangxi Medical University,Guangxi Zhuang Autonomous Region,Nanning510120,China;Department of Infectious Diseases,Laibin People's Hospital,Guangxi Zhuang Autonomous Region,Laibin546199,China)
出处
《中国当代医药》
2026年第2期118-122,共5页
China Modern Medicine
